Showing 1 - 10 of 33 records.

131-I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma

  • Conditions: Adult Studies, Cancer - Neuroblastoma
  • Gender: Female, Male

Provide palliative therapy with MIBG for patients with advanced neuroblastoma Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma ...More

ADVL1011: A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Hemangioma and Vascular Malformation, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.  ...More

ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...More

ADVL1212: A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL.

  • Conditions: Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some ...More

ADVL1312: A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the grow ...More

ADVL1322: A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

  • Conditions: Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma
  • Gender: Female, Male

PURPOSE: The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, no ...More

ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma
  • Gender: Female, Male

PURPOSE: The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be to establish the maximum tolerated pediatric doses of tablet formulation; to investigate ...More

ADVL1522: A Phase II Study of IMGN901 (Lorvotuzumab Mertansine) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

  • Conditions: Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma

PURPOSE: This phase II trial studies how well lorvotuzumab mertansine works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond ...More

ADVL1621: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

  • Conditions: Cancer - Leukemia and Lymphoma, Cancer - Neuroblastoma
  • Gender: Female, Male

PURPOSE: This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. Part 1 will find the maximum tolerated dose (MTD)/maximum administered ...More

ANBL09P1: A COG Pilot Study of Intensive Induction Therapy and 131I-MIBG With Myeloablative Carboplatin, Etoposide and Melphalan (CEM) for Newly Diagnosed High-Risk Neuroblastoma

  • Conditions: Cancer - Neuroblastoma
  • Gender: Female, Male

Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A p ...More

Contact Us

hospital

Adult Participants or Parents of Participants:

Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at clinicalstudies@cchmc.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.

Sponsors and Investigators:

The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.